ClinicalTrials.gg
TerminatedNCT03298113Updated Dec 2, 2024Results posted

Comparative Study to Assess an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis

An interventional study of Cavilon Advanced Skin Protectant and IAD Hospital Standard Care in Incontinence-associated Dermatitis, sponsored by Solventum US LLC. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment

Why this study was terminated
slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the clinical study is to assess the effects of 3M Cavilon Advanced Skin Protectant in comparison to different local IAD care regimes in hospitals (IAD: Incontinence-associated Dermatitis)

Read the detailed description

The purpose of the clinical study is to assess the effects of 3M Cavilon Advanced Skin Protectant in comparison to different local IAD care regimes in hospitals (IAD: incontinence-associated dermatitis). IAD is a skin damage caused by exposure to moisture and irritants such as urine and/or stool. The clinical appearance ranges from painful erythema to severe erosion and denudation/skin loss with or without secondary infection. The durable, long lasting skin protectant (3M study device) is formulated to attach to moist or wet skin surfaces (i.e., superficial, partial thickness skin loss) to provide better protection against moisture and irritants under challenging conditions.

02

Conditions studied

  • Incontinence-associated Dermatitis
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is the patient 18 years or older?
  2. Has the patient or their legally authorized representative signed the Form?
  3. Does the patient have IAD category 1A (IAD 1A: persistent redness without clinical signs of infection) or IAD category 2A (IAD 2A: skin loss without clinical signs of infection) in the study area (study area: the sacral region going down to the upper thighs, bordered approximately 5 cm below the gluteal fold?
  4. Is the patient incontinent and does stool and/or urine come into direct contact with the skin?
  5. Is the patient able to be turned/positioned with regard to skin assessment and photo documentation?
  6. Is there a reasonable expectation that the patient will remain in the hospital setting for at least 7 days?

Exclusion criteria

Exclusion Criteria:

  1. Is the patient pregnant or breast feeding?
  2. Does the patient have a known or allergy to acrylate or cyanoacrylate?
  3. Does the patient have a stage II, III, IV or unstageable pressure ulcer or other suspected deep tissue injury in the study area?
  4. Does the patient require topical treatment due to a fungal, bacterial or viral infection in the study area?
  5. Does the patient require treatment with topical medication or product other than IAD treatment in the study area?
  6. Does the patient have any other local dermatological disease or skin condition interfering with this study?
  7. Does the patient have any medical condition (e.g. end of life, planned elective surgery) that in the opinion of the investigator should exclude him/her from participating in the study?
  8. Does the patient participate in another study with a known or implied effect on skin barrier function?
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cavilon Advanced Skin Protectant

    Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.

    Device: Cavilon Advanced Skin Protectant

  • Other
    IAD Hospital Standard Care

    Marketed products are applied according to the IAD hospital standard care routine.

    Device: IAD Hospital Standard Care

Interventions

  • DeviceCavilon Advanced Skin Protectant

    Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.

  • DeviceIAD Hospital Standard Care

    Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.

06

What researchers measure

Primary outcomes

  1. Healing of IAD

    Number and percentage of patients completely healed (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool) Note: Due to the exploratory design no formal a priori hypothesis was defined for this study. The outcome measure type for all endpoints is "other pre-specified". The effects were analyzed using descriptive statistics. No confirmatory statements can be made about the effects and no comparative statements are possible. The sponsor decided to early terminate the study after 20 evaluable patients for the intention-to-treat analysis. Reason for the early termination was the slow enrollment rate of patients and overall short length of stay in hospital.

    Time frame: up to 21 days depending on length of hospitalization

Other outcomes

  1. Improvement of IAD Category

    Number and percentage of patients improved with regard to IAD category

    Time frame: Up to 21 days depending on length of hospitalization

  2. Re-epithelialization of Skin Loss

    Number and percentage of patients with 100% re-epithelialization of skin loss based on structured skin assessment (skin loss: skin is moist, as the epidermal layer is missing).

    Time frame: up to 21 days depending on length of hospitalization

  3. Time to Heal IAD

    Time to complete healing of IAD in the terms of days of treatment (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool)

    Time frame: Up to 21 days depending on length of hospitalization

  4. Time to Improve in IAD Category

    Time to improve in IAD category in the terms of days of treatment.

    Time frame: Up to 21 days depending on length of hospitalization

  5. Prevention of Skin Loss

    Protection of IAD category 1 patients from developing IAD category 2

    Time frame: up to 21 days depending on length of hospitalization

  6. Prevention of IAD Recurrence

    Protection of completely healed patients from recurrence of IAD during the study.

    Time frame: up to 21 days depending on length of hospitalization

  7. Product Cost: IAD 1A

    Mean average daily product cost per patient for IAD 1A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment. Note: One patient in the group treated with Cavilon Advanced Skin Protectant stayed only one day in the study due to an unrelated Severe Adverse Event at night. This had an impact on the product cost calculation. The application interval for Cavilon Advanced Skin Protectant in this study was three days (D1, D4, D7, D10, D13, D16, D19) , while the use of IAD products for standard hospital care was based on manufacturer recommendations, which could correspond to a daily interval with multiple applications.

    Time frame: up to 21 days depending on length of hospitalization

  8. Product Cost : IAD 2A

    Mean average daily cost per patient for IAD 2A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment

    Time frame: up to 21 days depending on length of hospitalization

  9. Use of Resources Involved in IAD Therapy

    Additional appointments with specialists involved in IAD therapy

    Time frame: Up to 21 days depending on length of hospitalization

  10. Nursing Time Related to Cleansing

    Nursing time to clean up incontinence episode

    Time frame: up to 21 days depending on length of hospitalization

  11. Nursing Time Related to Product Application

    Nursing time to administer skin protectants for IAD treatment

    Time frame: up to 21 days depending on length of hospitalization

  12. Pain Related to Cleansing: IAD 1A

    Pain scores related to clean up incontinence episode for IAD 1A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. For cleansing, IAD 1A patients treated with Cavilon Advanced Skin Protectant saw no change in pain due to having no pain reported at baseline nor last visit. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patients able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2, 4, 6, 8, 10), with higher score indicating more pain.

    Time frame: up to 21 days depending on length of hospitalization

  13. Pain Related to Cleansing: IAD 2A

    Pain scores related to clean up incontinence episode for IAD 2A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

    Time frame: up to 21 days depending on length of hospitalization

  14. Pain Related to Product Application: IAD 1A

    Pain scores related to application of skin protectants for IAD 1A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

    Time frame: up to 21 days depending on length of hospitalization

  15. Pain Related to Product Application: IAD 2A

    Pain scores related to application of skin protectants for IAD 2A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

    Time frame: up to 21 days depending on length of hospitalization

07

Results

Posted Sep 24, 2019
Limitations and caveats
Early termination due to slow enrollment rate and overall short length of hospital stay leading to small numbers of subjects analyzed (n = 20 ITT). No confirmatory and comparative statements can be made about the effects (exploratory study design).

Participant flow

Participant flow — Overall Study
MilestoneCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Started1010
Iad 1a34
Iad 2a76
Completed1010
Not completed00

Outcome measures

PrimaryHealing of IAD

Number and percentage of patients completely healed (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool) Note: Due to the exploratory design no formal a priori hypothesis was defined for this study. The outcome measure type for all endpoints is "other pre-specified". The effects were analyzed using descriptive statistics. No confirmatory statements can be made about the effects and no comparative statements are possible. The sponsor decided to early terminate the study after 20 evaluable patients for the intention-to-treat analysis. Reason for the early termination was the slow enrollment rate of patients and overall short length of stay in hospital.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Count of participants · Participants
Healing of IAD
ParticipantsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Not completely healed109
Completely healed01
Other pre-specifiedImprovement of IAD Category

Number and percentage of patients improved with regard to IAD category

Time frame:
Up to 21 days depending on length of hospitalization
Reported as:
Count of participants · Participants
Improvement of IAD Category
ParticipantsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Worsened00
Remained the Same88
Improved22
Other pre-specifiedRe-epithelialization of Skin Loss

Number and percentage of patients with 100% re-epithelialization of skin loss based on structured skin assessment (skin loss: skin is moist, as the epidermal layer is missing).

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Count of participants · Participants
Re-epithelialization of Skin Loss
ParticipantsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Not completely ephitelialized54
Completely epithelialized22
Other pre-specifiedTime to Heal IAD

Time to complete healing of IAD in the terms of days of treatment (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool)

Time frame:
Up to 21 days depending on length of hospitalization
Reported as:
Number · Days
Time to Heal IAD
DaysCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Time to Heal IAD—13.00
Other pre-specifiedTime to Improve in IAD Category

Time to improve in IAD category in the terms of days of treatment.

Time frame:
Up to 21 days depending on length of hospitalization
Reported as:
Mean · Days
Time to Improve in IAD Category
DaysCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Time to Improve in IAD Category9.50 ± 0.7075.50 ± 2.121
Other pre-specifiedPrevention of Skin Loss

Protection of IAD category 1 patients from developing IAD category 2

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Count of participants · Participants
Prevention of Skin Loss
ParticipantsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Worsened00
Remained the Same34
Improved00
Other pre-specifiedPrevention of IAD Recurrence

Protection of completely healed patients from recurrence of IAD during the study.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Number · IAD Recurrence Events
Prevention of IAD Recurrence
IAD Recurrence EventsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Prevention of IAD Recurrence—0
Other pre-specifiedProduct Cost: IAD 1A

Mean average daily product cost per patient for IAD 1A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment. Note: One patient in the group treated with Cavilon Advanced Skin Protectant stayed only one day in the study due to an unrelated Severe Adverse Event at night. This had an impact on the product cost calculation. The application interval for Cavilon Advanced Skin Protectant in this study was three days (D1, D4, D7, D10, D13, D16, D19) , while the use of IAD products for standard hospital care was based on manufacturer recommendations, which could correspond to a daily interval with multiple applications.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Euro
Product Cost: IAD 1A
EuroCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Product Cost: IAD 1A5.56 ± 3.800.75 ± 0.06
Other pre-specifiedProduct Cost : IAD 2A

Mean average daily cost per patient for IAD 2A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Euro
Product Cost : IAD 2A
EuroCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Product Cost : IAD 2A4.67 ± 2.531.21 ± 1.34
Other pre-specifiedUse of Resources Involved in IAD Therapy

Additional appointments with specialists involved in IAD therapy

Time frame:
Up to 21 days depending on length of hospitalization
Reported as:
Number · Appointments
Use of Resources Involved in IAD Therapy
AppointmentsCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Use of Resources Involved in IAD Therapy00
Other pre-specifiedNursing Time Related to Cleansing

Nursing time to clean up incontinence episode

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Minutes
Nursing Time Related to Cleansing
MinutesCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Nursing Time Related to Cleansing13.67 ± 7.9912.41 ± 8.17
Other pre-specifiedNursing Time Related to Product Application

Nursing time to administer skin protectants for IAD treatment

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Minutes
Nursing Time Related to Product Application
MinutesCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Nursing Time Related to Product Application2.49 ± 3.202.02 ± 1.90
Other pre-specifiedPain Related to Cleansing: IAD 1A

Pain scores related to clean up incontinence episode for IAD 1A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. For cleansing, IAD 1A patients treated with Cavilon Advanced Skin Protectant saw no change in pain due to having no pain reported at baseline nor last visit. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patients able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2, 4, 6, 8, 10), with higher score indicating more pain.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Change in score on a scale
Pain Related to Cleansing: IAD 1A
Change in score on a scaleCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Pain Related to Cleansing: IAD 1A0.00 ± 0.000-2.00 ± 3.464
Other pre-specifiedPain Related to Cleansing: IAD 2A

Pain scores related to clean up incontinence episode for IAD 2A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Change in score on a scale
Pain Related to Cleansing: IAD 2A
Change in score on a scaleCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Pain Related to Cleansing: IAD 2A-3.00 ± 4.147-0.33 ± 4.274
Other pre-specifiedPain Related to Product Application: IAD 1A

Pain scores related to application of skin protectants for IAD 1A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Change in score on a scale
Pain Related to Product Application: IAD 1A
Change in score on a scaleCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Pain Related to Product Application: IAD 1A0.00 ± 0.0000.00 ± 0.000
Other pre-specifiedPain Related to Product Application: IAD 2A

Pain scores related to application of skin protectants for IAD 2A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain.

Time frame:
up to 21 days depending on length of hospitalization
Reported as:
Mean · Change in score on a scale
Pain Related to Product Application: IAD 2A
Change in score on a scaleCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Pain Related to Product Application: IAD 2A-2.33 ± 4.082-1.20 ± 5.020

Adverse events

Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cavilon Advanced Skin Protectant0/10 (0%)1/10 (10%)6/10 (60%)
IAD Hospital Standard Care1/10 (10%)1/10 (10%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Cardiac arrestCardiac disorders1/100/10
Acute renal failureRenal and urinary disorders0/101/10
Most frequent other events
Most frequent other events
EventCavilon Advanced Skin ProtectantIAD Hospital Standard Care
Fungal infectionInfections and infestations2/102/10
Clostridium difficile infectionInfections and infestations1/100/10
Bacterial infectionInfections and infestations1/100/10
Device adhesion issueProduct Issues1/100/10
Vaginal mycosisInfections and infestations1/100/10

Baseline characteristics

Patients with Incontinence-associated Dermatitis

Age, Categorical
Age, Categorical(Participants)Cavilon Advanced Skin ProtectantIAD Hospital Standard CareTotal
<=18 years000
Between 18 and 65 years202
>=65 years81018
Sex: Female, Male
Sex: Female, Male(Participants)Cavilon Advanced Skin ProtectantIAD Hospital Standard CareTotal
Female8513
Male257
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Cavilon Advanced Skin ProtectantIAD Hospital Standard CareTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Cavilon Advanced Skin ProtectantIAD Hospital Standard CareTotal
Belgium448
Germany6612
08

Study locations

3 sites
  • Universitair Ziekenhuis Gent
    Gent, East Flanders 9000, Belgium
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • University Hospital Southampton
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jul 2018, 7 months.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Oct 2, 2017
StartActual
Nov 17, 2017
Primary completionActual
Jul 10, 2018
CompletionActual
Jul 10, 2018
Results first posted
Sep 24, 2019
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03298113
Lead sponsor
Solventum US LLC
Collaborators
3M
Responsible party
Sponsor
First posted
Oct 2, 2017
Start date
Nov 17, 2017
Primary completion
Jul 10, 2018
Completion
Jul 10, 2018
Results posted
Sep 24, 2019
Last update
Dec 2, 2024

Study contacts

Matthew M. Cooper, MD
study director · 3M

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion